CINECA IRIS Institutional Research Information System

SALANI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.844
AS - Asia 1.584
EU - Europa 969
SA - Sud America 239
AF - Africa 111
OC - Oceania 4
Totale 4.751
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.789
SG - Singapore 637
CN - Cina 412
IT - Italia 338
HK - Hong Kong 233
BR - Brasile 197
SE - Svezia 142
DE - Germania 100
GB - Regno Unito 84
VN - Vietnam 67
CI - Costa d'Avorio 54
KR - Corea 47
AT - Austria 43
RU - Federazione Russa 43
FI - Finlandia 40
IN - India 40
BG - Bulgaria 39
FR - Francia 36
JP - Giappone 25
NL - Olanda 24
CA - Canada 22
PL - Polonia 21
MX - Messico 20
AR - Argentina 19
NG - Nigeria 19
BD - Bangladesh 18
TR - Turchia 18
IQ - Iraq 15
PK - Pakistan 12
SN - Senegal 11
ES - Italia 10
ID - Indonesia 10
LT - Lituania 9
VE - Venezuela 9
CH - Svizzera 7
SA - Arabia Saudita 7
UA - Ucraina 7
ZA - Sudafrica 7
BE - Belgio 6
EC - Ecuador 6
RO - Romania 6
UZ - Uzbekistan 6
CZ - Repubblica Ceca 5
IR - Iran 5
KE - Kenya 5
MA - Marocco 5
MY - Malesia 5
JO - Giordania 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
CR - Costa Rica 3
EG - Egitto 3
LB - Libano 3
TW - Taiwan 3
AL - Albania 2
AO - Angola 2
AZ - Azerbaigian 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GD - Grenada 2
HN - Honduras 2
IE - Irlanda 2
PE - Perù 2
PH - Filippine 2
TN - Tunisia 2
UY - Uruguay 2
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CO - Colombia 1
EE - Estonia 1
GY - Guiana 1
IL - Israele 1
IS - Islanda 1
JM - Giamaica 1
KH - Cambogia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TM - Turkmenistan 1
TT - Trinidad e Tobago 1
Totale 4.751
Salva come PNG Salva come JPEG
Città #
Singapore 357
Ashburn 301
Hong Kong 229
Dallas 210
Santa Clara 198
Shanghai 116
Chandler 90
Hefei 80
Los Angeles 71
New York 69
Beijing 64
Milan 63
Boardman 57
Fairfield 55
Abidjan 54
Munich 52
Seoul 47
Council Bluffs 43
Sofia 39
London 37
Florence 34
Seattle 32
Vienna 31
Buffalo 27
Pisa 25
Colorado Springs 23
Turku 22
Ho Chi Minh City 20
Woodbridge 20
Lagos 19
Tokyo 19
Lawrence 18
Princeton 18
Warsaw 18
Cambridge 17
Redondo Beach 16
Wilmington 16
Frankfurt am Main 15
Hyderabad 13
Istanbul 13
Kent 13
Nuremberg 13
Hanoi 12
Houston 12
Ogden 12
São Paulo 12
Dakar 11
Medford 11
Düsseldorf 10
Lappeenranta 10
Mexico City 10
Quanzhou 10
Chicago 9
Denver 9
Rome 9
Baghdad 8
Boston 8
Cascina 8
Helsinki 8
Montreal 8
Portsmouth 8
San Diego 8
Stockholm 8
Ann Arbor 7
Brooklyn 7
Chennai 7
Fuzhou 7
Guangzhou 7
Lauterbourg 7
Orem 7
Poplar 7
The Dalles 7
Salt Lake City 6
Tashkent 6
Curitiba 5
Da Nang 5
Dhaka 5
Goiânia 5
Jeddah 5
Karachi 5
Norwalk 5
Phoenix 5
Rio de Janeiro 5
Salvador 5
Turin 5
Vicopisano 5
Amman 4
Amsterdam 4
Ankara 4
Atlanta 4
Bedizzole 4
Brussels 4
Castiglione Chiavarese 4
Livorno 4
Nairobi 4
Olomouc 4
Osaka 4
Piombino 4
Roubaix 4
Toronto 4
Totale 3.066
Salva come PNG Salva come JPEG
Nome #
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 170
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 156
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 143
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 137
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 137
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 135
Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies 134
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 127
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients 126
Correction to: Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies 123
Invasive Meningococcal Disease due to group C N. meningitidis ST11 (cc11): The Tuscany cluster 2015–2016 118
Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients 116
Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer 111
Dynamic profiling of the immune tumor microenvironment in locally advanced gastric cancer treated with perioperative chemotherapy 109
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 103
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 103
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib 100
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 97
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 96
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 95
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 94
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 91
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 90
Combination chemotherapy in patients with advanced pancreatic cancer with an eastern cooperative oncology group performance status of 2: Lights and shadows of a frail route 90
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 89
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 89
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 87
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 84
Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice 84
Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single institution study 82
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 78
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 75
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma 72
In Reply 68
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer 67
Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence 67
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 66
Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Carcinomatosis: The Need for Clear Answers Through Proper Questions 63
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action 62
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 61
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 61
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 60
null 59
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 54
Evolving Landscape in Liver Transplantation for Hepatocellular Carcinoma: From Stage Migration to Immunotherapy Revolution 53
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy 53
Comprehensive analysis of differentially expressed miRNAs in hepatocellular carcinoma: Prognostic, predictive significance and pathway insights 53
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 52
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 51
null 48
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab 47
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 45
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis 42
Comprehensive analysis of differentially expressed miRNAs in Hepatocellular carcinoma: prognostic significance and pathway insights 37
null 34
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis 25
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib 23
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 20
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 18
Precision epigenetic therapies in oncology 16
Attenuation-based estimation of myocardial extracellular volume from ECG-ungated whole-body CT examinations as an early biomarker of chemotherapy-induced cardiotoxicity: preliminary findings 13
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 6
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 6
Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance 6
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 6
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 6
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 5
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 5
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 5
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study 1
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 1
Totale 4.906
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.753
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.753
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202173 0 0 0 0 0 20 3 5 11 11 10 13
2021/2022204 0 1 3 6 42 41 6 2 19 14 22 48
2022/2023465 50 70 34 15 51 59 6 36 94 2 39 9
2023/2024424 21 41 42 26 58 40 65 16 5 17 41 52
2024/20251.999 14 99 46 84 151 310 132 96 172 193 264 438
2025/20261.642 233 314 270 248 348 229 0 0 0 0 0 0
Totale 4.906